Newsroom | 38980 results

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking the company’s proposed acquisition of JenaValve Technology. As a result, Edwards will not acquire JenaValve. Edwards disagrees with the decision and believes that the acquisition would have been in the best interest of a large, growing and underserved group of pati...

BOCA RATON, Fla.--(BUSINESS WIRE)--Il Cataltheia Group e la sua controllata, Bruno Vision Care LLC, azienda leader nell'innovazione della salute degli occhi, oggi ha annunciato che la Food and Drug Administration (FDA) statunitense ha approvato la prima e unica lente a contatto morbida per la presbiopia che utilizza la tecnologia brevettata di progettazione ottica Extended Depth of Focus (EDOF), dando il via alla distribuzione commerciale negli Stati Uniti. Deseyne® offre una focalizzazione flu...

GOLDEN, Colo.--(BUSINESS WIRE)--Registrational Phase 3 study for advanced melanoma immunotherapy delivered with PharmaJet's IM Needle-free System planned for second half 2026....

LOS ANGELES--(BUSINESS WIRE)--Automated Industrial Robotics Inc. (“AIR” or the “Company”) today announced the acquisition of KAON Automation (“KAON”), an Ireland-based industrial automation company that delivers advanced automation solutions for leading manufacturing companies globally. In addition to strengthening AIR’s existing presence in Ireland, the transaction expands the Company’s presence in the medical and life sciences end markets and enhances its capabilities across precision assembl...

NEW YORK--(BUSINESS WIRE)--Real Chemistry launches RC Resolve, a healthcare advisory practice helping leaders navigate value inflection points....

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025. Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $20.7 million and...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery. Lilly TuneLab was established to make advanced AI/ML model...

PALO ALTO, Calif.--(BUSINESS WIRE)--AirNexis Therapeutics, a clinical stage biotech company developing therapeutics for pulmonary diseases, today announced the close of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor in Phase 2 development for chronic obstructive pulmonary disease (COPD) from Haisco Pharmaceutical Group. The over-subscribed Series A was led by Frazier Life Sciences, with participation from OrbiMed, SR One, Life Sciences at Goldman Sachs Alt...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones. Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology,...

BOSTON--(BUSINESS WIRE)--Elucid today announced that, effective January 1, 2026, its Plaque-IQ™ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology. Quantitative coronary plaque analysis...